Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
T cells modified for expression of Chimeric Antigen Receptors (CARs) were the first gene-modified cell products approved for use in cancer immunotherapy. CAR-T cells engineered with gammaretroviral or lentiviral vectors (RVs/LVs) targeting B-cell lymphomas and leukemias have shown excellent clinical efficacy and no malignant transformation due to insertional mutagenesis to date. Large-scale production of RVs/LVs under good-manufacturing practices for CAR-T cell manufacturing has soared in recent years. However, manufacturing of RVs/LVs remains complex and costly, representing a logistical bottleneck for CAR-T cell production. Emerging gene-editing technologies are fostering a new paradigm in synthetic biology for the engineering and production of CAR-T cells. Firstly, the generation of the modular reagents utilized for gene editing with the CRISPR-Cas systems can be scaled-up with high precision under good manufacturing practices, are interchangeable and can be more sustainable in the long-run through the lower material costs. Secondly, gene editing exploits the precise insertion of CARs into defined genomic loci and allows combinatorial gene knock-ins and knock-outs with exciting and dynamic perspectives for T cell engineering to improve their therapeutic efficacy. Thirdly, allogeneic edited CAR-effector cells could eventually become available as “off-the-shelf” products. This review addresses important points to consider regarding the status quo, pending needs and perspectives for the forthright evolution from the viral towards gene editing developments for CAR-T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Chimeric antigen receptor (CAR) T cells have shown transformative efficacy in both B cell malignancies1,2 and, more recently, autoimmune diseases,3”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 1×
“RVs/LVs have relied mostly on the third generation packaging system, whereby four plasmids are used for expression of the backbone vector, gag/pol, rev and env (19, 20).”
MethodIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560 · cited 1×
“For BCMA targeted CAR-T therapies, CRS occurred within 1-7 days after infusion (98, 99).”
BackgroundAbramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31366-0 · Cited by 2,430
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977 · cited 2×
“An improvement was obtained with SIN mutations in the viral 3’LTR, disrupting the promoter/enhancer activity of the LTRs and enhancing the controlled expression through the internal promoter in the vector, and thereby minimizing the downstream expression of proto-oncogenes that could promote insertional mutagenesis (3…”
BackgroundMethodKosicki, M., Tomberg, K., & Bradley, A. (2018) · Nature Biotechnology · doi:10.1038/nbt.4192 · Cited by 1,883
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 8×
“They combined transfection of anti-CD3/CD28-stimulated T cells June 2022 | Volume 13 | Article 865424 with Cas9-single guide (sg)RNA ribonucleoprotein (RNP) complexes followed by transduction with a recombinant adeno-associated virus serotype 6 (rAAV6) to deliver the DNA donor template and homology-directed DNA repair…”
MethodInfluentialBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Research works printed but not linked: 73
- Naldini, 2016, Lentiviral Vectors, Two Decades Later, Science, 353, 10.1126/science.aah6192 · DOI · Paper page
- Blaese, 1995, T Lymphocyte-Directed Gene Therapy for ADA- SCID: Initial Trial Results After 4 Years, Science, 270, 10.1126/science.270.5235.475 · DOI · Paper page
- Kraunus, 2004, Self-Inactivating Retroviral Vectors With Improved RNA Processing, Gene Ther, 11, 10.1038/sj.gt.3302309 · DOI
- Tucci, 2021, Update on Clinical Ex Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases, Mol Ther, 29, 489, 10.1016/j.ymthe.2020.11.020 · DOI
- Biasco, 2018, Analyzing the Genotoxicity of Retroviral Vectors in Hematopoietic Cell Gene Therapy, Mol Ther Methods Clin Dev, 8, 21, 10.1016/j.omtm.2017.10.002 · DOI
- Porter, 2011, Chimeric Antigen Receptor Therapy for B-Cell Malignancies, J Cancer, 2, 10.7150/jca.2.331 · DOI
- Locke, 2017, Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma, Mol Ther, 25, 10.1016/j.ymthe.2016.10.020 · DOI · Paper page
- Jain, 2021, Outcomes and Management of Patients With Mantle Cell Lymphoma After Progression on Brexucabtagene Autoleucel Therapy, Br J Haematol, 192, 10.1111/bjh.17197 · DOI
- Pearson, 2022, Paediatric Strategy Forum for Medicinal Product Development of Chimeric Antigen Receptor T-Cells in Children and Adolescents With Cancer: ACCELERATE in Collaboration With the European Medicines Agency With Participation of the Food and Drug Administration, Eur J Cancer, 160, 10.1016/j.ejca.2021.10.016 · DOI
- Monjezi, 2017, Enhanced CAR T-Cell Engineering Using non-Viral Sleeping Beauty Transposition From Minicircle Vectors, Leukemia, 31, 10.1038/leu.2016.180 · DOI · Paper page
- Magnani, 2020, Sleeping Beauty-Engineered CAR T Cells Achieve Antileukemic Activity Without Severe Toxicities, J Clin Invest, 130, 10.1172/JCI138473 · DOI · Paper page
- Rahrmann, 2019, Sleeping Beauty Screen Identifies RREB1 and Other Genetic Drivers in Human B-Cell Lymphoma, Mol Cancer Res, 17, 10.1158/1541-7786.MCR-18-0582 · DOI
- Barrett, 2013, Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice With Advanced Leukemia, Hum Gene Ther, 24, 10.1089/hum.2013.075 · DOI · Paper page
- Olbrich, 2017, Reconstructing the Immune System With Lentiviral Vectors, Virus Genes, 53, 10.1007/s11262-017-1495-2 · DOI
- Brandt, 2020, Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review, Front Immunol, 11, 10.3389/fimmu.2020.00326 · DOI · Paper page
- Zhao, 2015, Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells, Cancer Cell, 28, 10.1016/j.ccell.2015.09.004 · DOI · Paper page
- Zhang, 2021, Optimization of Metabolism to Improve Efficacy During CAR-T Cell Manufacturing, J Transl Med, 19, 499, 10.1186/s12967-021-03165-x · DOI
- Chmielewski, 2014, Of CARs and TRUCKs: Chimeric Antigen Receptor (CAR) T Cells Engineered With an Inducible Cytokine to Modulate the Tumor Stroma, Immunol Rev, 257, 83, 10.1111/imr.12125 · DOI · Paper page
- Castellarin, 2018, Driving Cars to the Clinic for Solid Tumors, Gene Ther, 25, 10.1038/s41434-018-0007-x · DOI
- Wilkie, 2012, Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling, J Clin Immunol, 32, 10.1007/s10875-012-9689-9 · DOI · Paper page
- Bielamowicz, 2018, Trivalent CAR T Cells Overcome Interpatient Antigenic Variability in Glioblastoma, Neuro Oncol, 20, 10.1093/neuonc/nox182 · DOI · Paper page
- Lanitis, 2013, Chimeric Antigen Receptor T Cells With Dissociated Signaling Domains Exhibit Focused Antitumor Activity With Reduced Potential for Toxicity In Vivo, Cancer Immunol Res, 1, 43, 10.1158/2326-6066.CIR-13-0008 · DOI · Paper page
- Chmielewski, 2017, CAR T Cells Releasing IL-18 Convert to T-Bet(high) FoxO1(low) Effectors That Exhibit Augmented Activity Against Advanced Solid Tumors, Cell Rep, 21, 10.1016/j.celrep.2017.11.063 · DOI · Paper page
- Song, 2016, In Vivo Antitumor Activity of a Recombinant IL7/IL15 Hybrid Cytokine in Mice, Mol Cancer Ther, 15, 10.1158/1535-7163.MCT-16-0111 · doi:10.1158/1535-7163.mct-16-0111
- Ma, 2020, Interleukin-23 Engineering Improves CAR T Cell Function in Solid Tumors, Nat Biotechnol, 38, 10.1038/s41587-019-0398-2 · DOI · Paper page
- Chmielewski, 2015, TRUCKs: The Fourth Generation of CARs, Expert Opin Biol Ther, 15, 10.1517/14712598.2015.1046430 · DOI · Paper page
- Pincha, 2010, Lentiviral Vectors for Immunization: An Inflammatory Field, Expert Rev Vaccines, 9, 10.1586/erv.10.9 · DOI
- Bialek-Waldmann, 2021, Induced Dendritic Cells Co-Expressing GM-CSF/IFN-Alpha/Twt1 Priming T and B Cells and Automated Manufacturing to Boost GvL, Mol Ther Methods Clin Dev, 21, 10.1016/j.omtm.2021.04.004 · DOI
- Perry, 2021, Lentiviral Vector Bioprocessing, Viruses, 13, 1, 10.3390/v13020268 · DOI · Paper page
- Labbe, 2021, Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives, Viruses, 13, 1, 10.3390/v13081528 · DOI
- Kohl, 2018, CAR T Cells in Trials: Recent Achievements and Challenges That Remain in the Production of Modified T Cells for Clinical Applications, Hum Gene Ther, 29, 10.1089/hum.2017.254 · DOI · Paper page
- Buning, 2021, Gene Therapy "Made in Germany": A Historical Perspective, Analysis of the Status Quo, and Recommendations for Action by the German Society for Gene Therapy, Hum Gene Ther, 32, 10.1089/hum.2021.29178.hbu · DOI
- Vucinic, 2021, Production and Application of CAR T Cells: Current and Future Role of Europe, Front Med (Lausanne), 8, 10.3389/fmed.2021.713401 · DOI
- Aleksandrova, 2019, Functionality and Cell Senescence of CD4/ CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy(R) Platform, Transfus Med Hemother, 46, 47, 10.1159/000495772 · DOI · Paper page
- Jinek, 2012, A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity, Science, 337, 10.1126/science.1225829 · DOI · Paper page
- Wiebking, 2021, Genome Editing of Donor-Derived T-Cells to Generate Allogenic Chimeric Antigen Receptor-Modified T Cells: Optimizing Alphabeta T Cell-Depleted Haploidentical Hematopoietic Stem Cell Transplantation, Haematologica, 106, 10.3324/haematol.2019.233882 · DOI · Paper page
- Razeghian, 2021, A Deep Insight Into CRISPR/Cas9 Application in CAR-T Cell-Based Tumor Immunotherapies, Stem Cell Res Ther, 12, 428, 10.1186/s13287-021-02510-7 · DOI
- Ode, 2020, CRISPR-Mediated Non-Viral Site-Specific Gene Integration and Expression in T Cells: Protocol and Application for T-Cell Therapy, Cancers (Basel), 12, 1, 10.3390/cancers12061704 · DOI
- Kath, 2022, Pharmacological Interventions Enhance Virus-Free Generation of TRAC-Replaced CAR T Cells, Mol Ther Meth Clin Dev, 25, 10.1016/j.omtm.2022.03.018 · DOI · Paper page
- Muller, 2021, Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance, Front Immunol, 12, 10.3389/fimmu.2021.686439 · DOI
- Jing, 2021, Cas9-Cleavage Sequences in Size-Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T Cells, Small Methods, 5, 10.1002/smtd.202100071 · DOI
- Nguyen, 2020, Polymer-Stabilized Cas9 Nanoparticles and Modified Repair Templates Increase Genome Editing Efficiency, Nat Biotechnol, 38, 10.1038/s41587-019-0325-6 · DOI · Paper page
- Gomes-Silva, 2017, CD7-Edited T Cells Expressing a CD7-Specific CAR for the Therapy of T-Cell Malignancies, Blood, 130, 10.1182/blood-2017-01-761320 · DOI · Paper page
- Blache, 2021, Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications, Front Immunol, 12, 10.3389/fimmu.2021.658314 · DOI · Paper page
- Lu, 2020, Safety and Feasibility of CRISPR-Edited T Cells in Patients With Refractory non-Small-Cell Lung Cancer, Nat Med, 26, 10.1038/s41591-020-0840-5 · DOI · Paper page
- Sheridan, 2022, Off-The-Shelf, Gene-Edited CAR-T Cells Forge Ahead, Despite Safety Scare, Nat Biotechnol, 40, 5, 10.1038/d41587-021-00027-1 · doi:10.1038/d41587-021-00027-1
- Morgan, 2020, Use of Cell and Genome Modification Technologies to Generate Improved "Off-The-Shelf" CAR T and CAR NK Cells, Front Immunol, 11, 10.3389/fimmu.2020.01965 · DOI
- Amini, 2021, CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients, Mol Ther, 29, 32, 10.1016/j.ymthe.2020.09.011 · DOI
- Bothmer, 2020, Detection and Modulation of DNA Translocations During Multi-Gene Genome Editing in T Cells, CRISPR J, 3, 10.1089/crispr.2019.0074 · DOI · Paper page
- Turchiano, 2021, Quantitative Evaluation of Chromosomal Rearrangements in Gene-Edited Human Stem Cells by CAST-Seq, Cell Stem Cell, 28, 1136, 10.1016/j.stem.2021.02.002 · DOI · Paper page
- Modlich, 2006, Cell-Culture Assays Reveal the Importance of Retroviral Vector Design for Insertional Genotoxicity, Blood, 108, 10.1182/blood-2005-08-024976 · DOI · Paper page
- Sachdeva, 2020, Author Correction: Repurposing Endogenous Immune Pathways to Tailor and Control Chimeric Antigen Receptor T Cell Functionality, Nat Commun, 11, 2357, 10.1038/s41467-020-16301-w · doi:10.1038/s41467-020-16301-w
- Wagner, 2021, Immunogenicity of CAR T Cells in Cancer Therapy, Nat Rev Clin Oncol, 18, 10.1038/s41571-021-00476-2 · DOI · Paper page
- Brentjens, 2007, Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts, Clin Cancer Res, 13, 10.1158/1078-0432.CCR-07-0674 · DOI · Paper page
- Tsukahara, 2013, CD19 Target-Engineered T-Cells Accumulate at Tumor Lesions in Human B-Cell Lymphoma Xenograft Mouse Models, Biochem Biophys Res Commun, 438, 10.1016/j.bbrc.2013.07.030 · DOI
- MacLeod, 2017, Integration of a CD19 CAR Into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells, Mol Ther, 25, 10.1016/j.ymthe.2017.02.005 · DOI · Paper page
- Stripecke, 2020, Innovations, Challenges, and Minimal Information for Standardization of Humanized Mice, EMBO Mol Med, 12, 10.15252/emmm.201708662 · DOI · Paper page
- Daniel, 2009, A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In Vitro, Cancer Res, 69, 10.1158/0008-5472.CAN-08-4210 · DOI · Paper page
- Takenaka, 2007, Polymorphism in Sirpa Modulates Engraftment of Human Hematopoietic Stem Cells, Nat Immunol, 8, 10.1038/ni1527 · DOI · Paper page
- Shultz, 2005, Human Lymphoid and Myeloid Cell Development in NOD/LtSz-Scid IL2R Gamma Null Mice Engrafted With Mobilized Human Hemopoietic Stem Cells, J Immunol, 174, 10.4049/jimmunol.174.10.6477 · DOI · Paper page
- du Manoir, 2014, Breast Tumor PDXs are Genetically Plastic and Correspond to a Subset of Aggressive Cancers Prone to Relapse, Mol Oncol, 8, 10.1016/j.molonc.2013.11.010 · DOI
- Zhu, 2015, Establishment and Characterization of Patient-Derived Tumor Xenograft Using Gastroscopic Biopsies in Gastric Cancer, Sci Rep, 5, 8542, 10.1038/srep08542 · DOI
- Hegde, 2016, Tandem CAR T Cells Targeting HER2 and IL13Ralpha2 Mitigate Tumor Antigen Escape, J Clin Invest, 126, 10.1172/JCI83416 · DOI · Paper page
- Rabilloud, 2021, Single-Cell Profiling Identifies Pre-Existing CD19-Negative Subclones in a B-ALL Patient With CD19-Negative Relapse After CAR-T Therapy, Nat Commun, 12, 865, 10.1038/s41467-021-21168-6 · DOI
- Teng, 2019, Chimeric Antigen Receptor-Modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-Derived Colon Carcinoma Xenograft Model, J Immunother, 42, 33, 10.1097/CJI.0000000000000251 · DOI · Paper page
- Labani-Motlagh, 2020, The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses, Front Immunol, 11, 10.3389/fimmu.2020.00940 · DOI · Paper page
- Shi, 2021, CAR T Cells Targeting CD99 as an Approach to Eradicate T-Cell Acute Lymphoblastic Leukemia Without Normal Blood Cells Toxicity, J Hematol Oncol, 14, 162, 10.1186/s13045-021-01178-z · DOI
- Cogels, 2021, Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research, Front Oncol, 11, 10.3389/fonc.2021.784947 · DOI
- Jin, 2019, Modeling Anti-CD19 CAR T Cell Therapy in Humanized Mice With Human Immunity and Autologous Leukemia, EBioMedicine, 39, 10.1016/j.ebiom.2018.12.013 · DOI
- Slabik, 2020, CAR-T Cells Targeting Epstein-Barr Virus Gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease, Mol Ther Oncolytics, 18, 10.1016/j.omto.2020.08.005 · DOI
- Leick, 2021, Clinical Perspective: Treatment of Aggressive B Cell Lymphomas With FDA-Approved CAR-T Cell Therapies, Mol Ther, 29, 10.1016/j.ymthe.2020.10.022 · DOI
- Graham, 2021, Gene-Edited Healthy Donor CAR T Cells Show Superior Anti-Tumour Activity Compared to CAR T Cells Derived From Patients With Lymphoma in an In Vivo Model of High-Grade Lymphoma, Leukemia, 35, 10.1038/s41375-021-01324-z · DOI
- Brown, 2021, Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis, Front Oncol, 11, 10.3389/fonc.2021.634445 · DOI
Cited by
Glaser, V., Flugel, C., Kath, J., Du, W., Drosdek, V., Franke, C., Stein, M., Pruß, A., Schmueck-Henneresse, M., Volk, H.-D., et al. (2023) · Genome biology · doi:10.1186/s13059-023-02928-7 · Cited by 65
Self-citationPicht, S., Farrera-Sal, M., Hiller, A. L., Brumhard, S., Klaas, A. M., Schulenberg, S., Friedrich, R., Scholz, C., Hemmerling, L., Simon, D. N., et al. (2026) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2026.102929 · Cited by 7
Metadata
- Authors
- Wagner, D. L., Koehl, U., Chmielewski, M., Scheid, C., & Stripecke, R.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-06-17
- Volume
- 13
- ISSN
- 1664-3224
- Cited by
- 65
- References
- 29
- Funders
- Deutsches Zentrum für Infektionsforschung
- Deutsche Krebshilfe
- Jackson Laboratory
- Horizon 2020 Framework Programme
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing. https://app.cochat.ai/papers/10.3389/fimmu.2022.865424
- The paper
- Wagner, D. L., Koehl, U., Chmielewski, M., Scheid, C., & Stripecke, R. (2022). Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.865424
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.